ONCR Oncorus Inc.

17.77
-0.05  -0%
Previous Close 17.82
Open 17.91
52 Week Low 14.6
52 Week High 19.3
Market Cap $388,201,359
Shares 21,845,884
Float 14,128,061
Enterprise Value $329,351,497
Volume 57,974
Av. Daily Volume 0
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
ONCR-177
Solid tumors
Phase 1
Phase 1
Phase 1 trial initiation announced July 16, 2020.

Latest News

  1. CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced that its President and Chief Executive Officer, Theodore (Ted) A. Ashburn, M.D., Ph.D., will present a company overview at the Chardan 4th Annual Genetic Medicines Conference, to be held virtually on Tuesday, October 6, 2020 at 4:15 p.m. ET.

    About Oncorus
    Oncorus is a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients. Using its two distinct proprietary platforms, the Company is developing a pipeline of intratumorally…

    CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced that its President and Chief Executive Officer, Theodore (Ted) A. Ashburn, M.D., Ph.D., will present a company overview at the Chardan 4th Annual Genetic Medicines Conference, to be held virtually on Tuesday, October 6, 2020 at 4:15 p.m. ET.

    About Oncorus

    Oncorus is a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients. Using its two distinct proprietary platforms, the Company is developing a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Oncorus' lead product candidate, ONCR-177, is an intratumorally administered viral immunotherapy based on its oncolytic HSV-1 platform, referred to as the oHSV Platform, which leverages the Herpes Simplex Virus type 1, or HSV-1, a virus which has been clinically proven to effectively treat certain cancers. For more information, please visit www.oncorus.com.

    Investors:

    John McCabe

    Media:

    Liz Melone

    Primary Logo

    View Full Article Hide Full Article
View All Oncorus Inc. News